1. Home
  2. CUZ vs AKRO Comparison

CUZ vs AKRO Comparison

Compare CUZ & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUZ
  • AKRO
  • Stock Information
  • Founded
  • CUZ 1958
  • AKRO 2017
  • Country
  • CUZ United States
  • AKRO United States
  • Employees
  • CUZ N/A
  • AKRO N/A
  • Industry
  • CUZ Real Estate Investment Trusts
  • AKRO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CUZ Real Estate
  • AKRO Health Care
  • Exchange
  • CUZ Nasdaq
  • AKRO Nasdaq
  • Market Cap
  • CUZ 4.7B
  • AKRO 3.9B
  • IPO Year
  • CUZ N/A
  • AKRO 2019
  • Fundamental
  • Price
  • CUZ $28.47
  • AKRO $49.23
  • Analyst Decision
  • CUZ Buy
  • AKRO Strong Buy
  • Analyst Count
  • CUZ 9
  • AKRO 7
  • Target Price
  • CUZ $32.11
  • AKRO $81.57
  • AVG Volume (30 Days)
  • CUZ 1.6M
  • AKRO 1.1M
  • Earning Date
  • CUZ 07-31-2025
  • AKRO 08-08-2025
  • Dividend Yield
  • CUZ 4.50%
  • AKRO N/A
  • EPS Growth
  • CUZ N/A
  • AKRO N/A
  • EPS
  • CUZ 0.37
  • AKRO N/A
  • Revenue
  • CUZ $917,942,000.00
  • AKRO N/A
  • Revenue This Year
  • CUZ $14.18
  • AKRO N/A
  • Revenue Next Year
  • CUZ $2.97
  • AKRO N/A
  • P/E Ratio
  • CUZ $76.63
  • AKRO N/A
  • Revenue Growth
  • CUZ 11.98
  • AKRO N/A
  • 52 Week Low
  • CUZ $24.07
  • AKRO $21.34
  • 52 Week High
  • CUZ $32.55
  • AKRO $58.40
  • Technical
  • Relative Strength Index (RSI)
  • CUZ 57.73
  • AKRO 48.60
  • Support Level
  • CUZ $27.46
  • AKRO $47.14
  • Resistance Level
  • CUZ $28.13
  • AKRO $50.19
  • Average True Range (ATR)
  • CUZ 0.56
  • AKRO 2.07
  • MACD
  • CUZ 0.18
  • AKRO 0.01
  • Stochastic Oscillator
  • CUZ 89.84
  • AKRO 49.13

About CUZ Cousins Properties Incorporated

Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: